Hypoxia-inducible factor 1 and cancer pathogenesis

IUBMB Life

Volumn 60, Issue 9, 2008, Pages 591-597

  Semenza, Gregg L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Autophagy; Cancer; Glycolysis; Hypoxia; Mitochondria; Respiration; ROS

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; OXYGEN; VON HIPPEL LINDAU PROTEIN; GLUCOSE; MYC PROTEIN; REACTIVE OXYGEN METABOLITE; VHL PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CARCINOGENESIS; DISEASE ASSOCIATION; ENERGY METABOLISM; GLUCOSE METABOLISM; IN VIVO STUDY; KIDNEY CARCINOMA; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; VON HIPPEL LINDAU DISEASE; ANIMAL; GENETICS; HOMEOSTASIS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; CARCINOMA, RENAL CELL; ENERGY METABOLISM; GLUCOSE; HOMEOSTASIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; OXYGEN; PROTO-ONCOGENE PROTEINS C-MYC; REACTIVE OXYGEN SPECIES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 56149089262     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.93     Document Type: Review

References (57)

1. Vogelstein, B. and Kinzler, K. W., eds. (1998) The Genetic Basis of Human Cancer, McGraw-Hill, New York.
2. Weinberg, R. A. (2007) The Biology of Cancer, Garland Science, New York.
3. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186.
4. Gasparini, G., Longo, R., Toi, M., and Ferrara, N. (2005) Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol. 2, 562-577.
5. Warburg, O. (1930) The Metabolism of Tumours, Arnold Constable, London.
6. Gatenby, R. A. and Gillies, R. J. (2004) Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891-899.
7. Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70.
8. Harris, A. L. (2002) Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2, 38-47.
9. Vaupel, P., Mayer, A., and Hockel, M. (2004) Tumor hypoxia and malignant progression. Methods Enzymol. 381, 335-356.
10. Brown, J. M. and Giaccia, A. J. (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408-1416.
11. Jain, R. K. (2003) Molecular regulation of vessel maturation. Nat. Med. 9, 685-693.
12. 2 tension. Proc. Natl. Acad. Sci. USA 92, 5510-5514.
13. 2 tension. Am. J. Physiol. 271, C1172-C1180.
14. Jiang, B.-H., Zheng, J. Z., Leung, S. W., Roe, R., and Semenza, G. L. (1997) Transactivation and inhibitory domains of hypoxia-inducible factor 1α: modulation of transcriptional activity by oxygen tension. J. Biol. Chem. 272, 19253-19260.
15. Schofield, C. J. and Ratcliffe, P. J. (2005) Signalling hypoxia by HIF hydroxylases. Biochem. Biophys. Res. Commun. 338, 617-626.
16. Kaelin, W. G. Jr. (2007) The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13, 680S-684S.
17. Peet, D. J., Lando, D., Whelan, D. A., Whitelaw, M. L., and Gorman, J. J. (2004) Oxygen-dependent asparagine hydroxylation. Methods Enzymol. 381, 467-487.
18. Semenza, G. L., Jiang, B.-H., Leung, S. W., Passantino, R., Concordet, J.-P., Maire, P., and Giallongo, A. (1996) Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 271, 32529-32537.
19. Ruas, J. L. and Poellinger, L. (2005) Hypoxia-dependent activation of HIF into a transcriptional regulator. Semin. Cell Dev. Biol. 16, 514-522.
20. Manalo, D. J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B. D., Ye, S. Q., Garcia, J. G., and Semenza, G. L. (2005) Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105, 659-669. (Pubitemid 40070750)
21. Elvidge, G. P., Glenny, L., Appelhoff, R. J., Ratcliffe, P. J., Ragoussis, J., and Gleadle, J. M. (2006) Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1α, HIF-2α, and other pathways. J. Biol. Chem. 281, 15215-15226.
22. Patel, S. A. and Simon, M. C. (2008) Biology of hypoxia-inducible factor 2α in development and disease. Cell Death Differ. 15, 628-634. (Pubitemid 351405065)
23. Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., and Ratcliffe, P. J. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275.
24. Kondo, K., Kim, K., Lechpammer, M., and Kaelin, W. G. Jr. (2003) Inhibition of HIF-2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, E83. (Pubitemid 39112142)
25. Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., and Kaelin, W. G. Jr. (2002) Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237-246. (Pubitemid 41039148)
26. Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., and Klausner, R. D. (2002) The contribution of VHL substrate binding and HIF-1α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247-255. (Pubitemid 41039149)
27. Mandriota, S. J., Turner, K. J., Davies, D. R., Murray, P. G., Morgan, N. V., Sowter, H. M., Wykoff, C. C., Maher, E. R., Harris, A. L., Ratcliff, P. J., and Maxwell, P. H. (2002) HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459-468.
28. Knebelmann, B., Ananth, S., Cohen, H. T., and Sukhatme, V. P. (1998) Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor. Cancer Res. 58, 226-231. (Pubitemid 28047059)
29. de Paulsen, N. Brychzy, A. Fournier, M. C., Klausner, R. D., Gnarra, J. R., Pause, A., and Lee, S. (2001) Role of transforming growth factor-α in von Hippel-Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc. Natl. Acad. Sci. USA 98, 1387-1392.
30. Gunaratnam, L., Morley, M., Franovic, A., de Paulsen, N., Mekhail, K., Parolin, D. A., Nakamura, E., Lorimer, I. A., and Lee, S. (2003) Hypoxia inducible factor activates the transforming growth factor-α/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem. 278, 44966-44974.
31. Krishnamachary, B., Berg-Dixon, S., Kelly, B., Agani, F., Feldser, D., Ferreira, G., Iyer, N., LaRusch, J., Pak, B., Taghavi, P., and Semenza, G. L. (2003) Regulation of colon carcinoma cell invasion by hypoxiainducible factor 1. Cancer Res. 63, 1138-1143. (Pubitemid 36278449)
32. Siemeister, G., Weindel, K., Mohrs, K., Barleon, B., Martiny-Baron, G., and Marmé, D. (1996) Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56, 2299-2301. (Pubitemid 26154077)
33. Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G. Jr., and Goldberg, M. A. (1996) Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA 93, 10595-10599.
34. Zagzag, D., Krishnamachary, B., Yee, H., Okuyama, H., Chiriboga, L., Ali, M. A., Melamed, J., and Semenza, G. L. (2005) Stromal cellderived factor-1α and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res. 65, 6178-6188. (Pubitemid 40994403)
35. Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., and W. Krek. (2003) Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425, 307-311. (Pubitemid 37158407)
36. Krishnamachary, B., Zagzag, D., Nagasawa, H., Rainey, K., Okuyama, H., Baek, J. H., and Semenza, G. L. (2006) Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res. 66, 2725-2731.
37. Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., and Comoglio P. M. (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-361. (Pubitemid 38340304)
38. Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q. T., Chi, J. T., Jeffrey, S. S., and Giaccia, A. J. (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440, 1222-1226.
39. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 12, 149-162.
40. Fukuda, R., Zhang, H., Kim, J. W., Shimoda, L., Dang, C. V., and Semenza, G. L. (2007) HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129, 111-122. (Pubitemid 46507584)
41. Kim, J. W., Tchernyshyov, I., Semenza, G. L., and Dang, C. V. (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177-185. (Pubitemid 43316523)
42. Zhang, H., Gao, P., Fukuda, R., Kumar, G., Krishnamachary, B., Zeller, K. I., Dang, C. V., and Semenza, G. L. (2007) HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11, 407-420. (Pubitemid 46670080)
43. Zhang, H., Bosch-Marce, M., Shimoda, L. A., Tan, Y. S., Baek, J. H., Wesley, J. B., Gonzalez, F. J., and Semenza, G. L. (2008) Mitochondrial autophagy is a HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem. 283, 10892-10903.
44. Guzy, R. D. and Schumacker, P. T. (2006) Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp. Physiol. 91, 807-819.
45. Knowles, H. J., Raval, R. R., Harris, A. L., and Ratcliffe, P. J. (2003) Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res. 63, 1764-1768. (Pubitemid 36460834)
46. Gao, P., Zhang, H., Dinavahi, R., Li, F., Xiang, Y., Raman, V., Bhujwalla, Z. M., Felsher, D. W., Cheng, L., Pevsner, J., Lee, L. A., Semenza, G. L., and Dang, C. V. (2007) HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12, 230-238. (Pubitemid 47333417)
47. Dang, C. V., Kim, J. W., Gao, P., and Yustein, J. (2008) The interplay between MYC and HIF in cancer. Nat. Rev. Cancer 8, 51-56.
48. Semenza, G. L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732.
49. Semenza, G. L. (2007) Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today 12, 853-859.
50. Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., and Bedi, A. (2000) Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev. 14, 34-44. (Pubitemid 30051577)
51. Stoeltzing, O., McCarty, M. F., Wey, J. S., Fan, F., Liu, W., Belcheva, A., Bucana, C. D., Semenza, G. L., and Ellis, L. M. (2004) Role of hypoxia-inducible factor 1α in gastric cancer cell growth, angiogenesis, and vessel maturation. J. Natl. Cancer Inst. 96, 946-956.
52. Melillo, G. (2007) Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev. 26, 341-352. (Pubitemid 47101663)
53. Isaacs, J. S., Jung, Y. J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., and Neckers, L. M. (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J. Biol. Chem. 277, 29936-29944.
54. 2-independent and HSP90 inhibitor-induced degradation of HIF-1α. Mol. Cell. 25, 207-217.
55. Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., Simons, J. W., and Semenza, G. L. (2000) Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60, 1541-1545. (Pubitemid 30183422)
56. Laughner, E., Taghavi, P., Chiles, K., Mahon, P. C., and Semenza, G. L. (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21, 3995-4004.
57. Fukuda, R., Hirota, K., Fan, F., Jung, Y. D., Ellis, L. M., and Semenza, G. L. (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 277, 38205-38211.